 Connection
Craig Jordan to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Craig Jordan has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.469 |
|
|
|
-
Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CT. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014 Oct; 28(10):1960-8.
Score: 0.086
-
Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008 Jun 15; 111(12):5654-62.
Score: 0.057
-
Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia. Expert Opin Biol Ther. 2005 Sep; 5(9):1147-52.
Score: 0.048
-
Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 02 01; 27(3):819-830.
Score: 0.034
-
Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clin Cancer Res. 2019 07 01; 25(13):4079-4090.
Score: 0.031
-
Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Mol Cancer Ther. 2017 10; 16(10):2058-2068.
Score: 0.027
-
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6669-E6678.
Score: 0.026
-
Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 2015 Jun 20; 6(17):14796-813.
Score: 0.024
-
Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015 Jun; 25(6):707-25.
Score: 0.023
-
Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther. 2014 Aug; 13(8):1979-90.
Score: 0.022
-
Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA. Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. PLoS One. 2014; 9(1):e85702.
Score: 0.021
-
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014 Jan; 124(1):222-36.
Score: 0.021
-
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
Score: 0.018
-
Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009 Sep; 23(9):1587-97.
Score: 0.016
-
Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood. 2008 Feb 01; 111(3):1644-53.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|